Head to Head Review: XTL Biopharmaceuticals (NASDAQ:XTLB) & Akebia Therapeutics (NASDAQ:AKBA)

Akebia Therapeutics (NASDAQ:AKBA) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Volatility and Risk

Akebia Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Akebia Therapeutics and XTL Biopharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1	2	4	0	2.43
XTL Biopharmaceuticals	1	0	0	0	1.00

Akebia Therapeutics presently has a consensus price target of $3.90, suggesting a potential upside of 335.51%. Given Akebia Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Akebia Therapeutics is more favorable than XTL Biopharmaceuticals.

Earnings and Valuation

This table compares Akebia Therapeutics and XTL Biopharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20 million	1.05	-$5.34 million	($0.11)	-8.14
XTL Biopharmaceuticals	$450,000.00	12.77	-$6.97 million	($0.64)	-3.79

Akebia Therapeutics has higher revenue and earnings than XTL Biopharmaceuticals. Akebia Therapeutics is trading at a lower price-to-earnings ratio than XTL Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Akebia Therapeutics and XTL Biopharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-13.54%	-88.88%	-7.74%
XTL Biopharmaceuticals	N/A	N/A	N/A

Institutional & Insider Ownership

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.